Welcome to our dedicated page for Azitra news (Ticker: AZTR), a resource for investors and traders seeking the latest updates and insights on Azitra stock.
Azitra Inc. develops clinical-stage precision dermatology therapies built around engineered proteins and topical live biotherapeutic products. Its pipeline includes ATR-12, an engineered S. epidermidis program for Netherton syndrome; ATR-04, an engineered S. epidermidis candidate for EGFR inhibitor-associated rash; and ATR-01, a program targeting ichthyosis vulgaris through delivery of recombinant human filaggrin.
Azitra news commonly covers patent protection, preclinical and clinical program updates, scientific presentations, business results, financing activity, shareholder meeting matters, and NYSE American listing-compliance notices. Company updates also reference its microbial discovery platform, artificial intelligence and machine-learning screening tools, and the use of genetically engineered bacteria and proteins for dermatology applications.
Azitra (NYSE: AZTR) reported its Q1 2025 financial results and provided business updates. The company secured up to $20 million in funding through a partnership with Alumni Capital LP and raised an additional $2.2 million through public offerings. Key developments include acceptance of a poster presentation at ASCO 2025 for their ATR-04 program targeting EGFR inhibitor-associated rash.
The company expects initial safety data from their ATR-12 Phase 1b trial for Netherton syndrome in 1H 2025, with topline results by year-end. They also plan to begin dosing patients in a Phase 1/2 trial for ATR-04 by mid-2025. Financial results show R&D expenses of $1.3 million, G&A expenses of $1.9 million, and a net loss of $3.1 million for Q1 2025. Cash position stands at $3.2 million as of March 31, 2025.
Azitra (NYSE American: AZTR) announced that its ATR04-484 program for treating EGFR inhibitor-associated rash will be presented at the 2025 ASCO Annual Meeting in Chicago (May 30-June 3, 2025). The company plans to dose the first patient in their Phase 1/2 clinical trial during the first half of 2025.
ATR04-484 is a live biotherapeutic product using an engineered Staphylococcus epidermidis strain, developed to treat skin rashes caused by EGFR inhibitor cancer treatments. The product has received Fast Track designation from the FDA for this indication. These rashes occur due to suppressed skin immunity and inflammation, often showing elevated IL-36γ and S. aureus levels.
EGFR inhibitors are cancer drugs targeting the EGFR protein, commonly used in treating non-small cell lung cancer and colorectal cancer. The complete ASCO abstract will be available on May 22, 2025.
Azitra (NYSE American: AZTR) has entered into a share purchase agreement with Alumni Capital LP for up to $20 million in funding over a 20-month period. The agreement allows Azitra to sell common stock and warrants to Alumni Capital at market-based prices, with Azitra maintaining full control over the timing and amount of sales.
The funding will support Azitra's clinical pipeline development of live biotherapeutic precision products for rare and severe dermatologic conditions, specifically focusing on Netherton Syndrome and EGFRi associated rash, which affects approximately 150,000 people in the U.S. The company aims to minimize dilution while maintaining shareholder value through this flexible funding arrangement.
Azitra (NYSE American: AZTR), a clinical-stage biopharmaceutical company specializing in precision dermatology, has announced its participation in the upcoming Microbiome Times Partnering Forum in Brussels, Belgium, scheduled for March 18-19, 2025.
Chief Operating Officer Travis Whitfill, Ph.D., MPH, will lead the company's presentation at the forum. The event will provide an opportunity for Azitra's management team to conduct one-on-one meetings with registered investors and potential partners. During these sessions, they will showcase their business and clinical development strategy, recent corporate achievements, and upcoming milestones.
Azitra (NYSE: AZTR) reported its full year 2024 financial results and business updates. The company initiated a Phase 1b trial for ATR-12 in Netherton syndrome patients, with initial safety data expected in H1 2025 and topline data by year-end 2025. The FDA cleared a Phase 1/2 study of ATR-04 for EGFRi-associated dermal toxicity and granted it Fast Track designation.
Financial highlights include: service revenue of $0.8K (down from $0.7M in 2023), R&D expenses of $4.7M (up from $3.6M), G&A expenses of $6.3M (up from $4.5M), and a net loss of $9.0M (improved from $11.3M in 2023). Cash position stood at $4.6M as of December 31, 2024, with additional $2.2M raised in early 2025.
The company completed public offerings totaling $15M and strengthened its IP portfolio. ATR-04 targets a market opportunity exceeding $1B, affecting approximately 150,000 US patients annually.
Azitra (NYSE American: AZTR) has announced a registered direct offering of 3,339,300 shares of common stock priced at $0.2785 per share, expected to raise approximately $930,000 in gross proceeds. The offering, scheduled to close on February 5, 2025, is being conducted with institutional investors through a securities purchase agreement.
The company plans to use the net proceeds for working capital and general corporate purposes. Maxim Group is serving as the sole placement agent for the offering, which is being made under an effective shelf registration statement on Form S-3 filed with the SEC on July 1, 2024, and declared effective on July 8, 2024.
Azitra (NYSE American: AZTR), a clinical stage biopharmaceutical company specializing in precision dermatology, has announced its participation in the upcoming BIO CEO & Investor Conference. The event will take place on February 10-11, 2025, in New York City.
The company's presentation is scheduled for February 10, 2025, at 3:45 p.m. ET in the Royale Room at The New York Marriott Marquis. Travis Whitfill, Chief Operating Officer, will lead the presentation.
During the conference, Azitra's management team will engage in one-on-one meetings with registered investors and potential partners. These meetings will focus on discussing the company's business and clinical development strategy, recent corporate achievements, and upcoming milestones.
Azitra (NYSE American: AZTR), a clinical stage biopharmaceutical company specializing in precision dermatology, has announced its participation in The Microcap Conference 2025. The presentation is scheduled for January 29, 2025, at 11:00 a.m. ET at the Borgata Hotel Casino & Spa in Atlantic City, NJ.
Chief Executive Officer Francisco Salva will lead the presentation in Studio C. During the conference, which runs from January 28-30, 2025, the company's management team will engage in one-on-one meetings with registered investors and potential partners. These meetings will focus on discussing Azitra's business and clinical development strategy, recent corporate achievements, and upcoming milestones.
Azitra (NYSE American: AZTR), a clinical-stage biopharmaceutical company specializing in precision dermatology, has announced the pricing of its public offering of 4,857,780 shares of common stock at $0.30 per share. The offering is expected to generate gross proceeds of approximately $1.5 million before deducting placement agent fees and other expenses.
The offering is scheduled to close on January 16, 2025, subject to customary conditions. The company plans to use the net proceeds for working capital and general corporate purposes. Maxim Group is serving as the sole placement agent for this offering, which is being conducted under an effective shelf registration statement previously filed with the SEC.
Azitra (NYSE American: AZTR), a clinical-stage biopharmaceutical company specializing in precision dermatology, has announced the commencement of a public offering of common stock and pre-funded warrants. Maxim Group will serve as the sole placement agent for the offering.
The company plans to utilize the net proceeds for working capital and general corporate purposes. The offering is being conducted through an effective shelf registration statement on Form S-3 filed with the SEC on July 1, 2024, and declared effective on July 8, 2024. The completion, size, and terms of the offering are subject to market conditions and cannot be guaranteed.